PR Newswire (Wed, 5:46PM)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
5,614 people get AMGN articles and Market Currents by email alert.
Get email alerts on AMGN »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
PR Newswire (Thu, 4:18PM)
-
-
PR Newswire (May 15, 2013)
-
-
-
-
-
-
-
PR Newswire (May 9, 2013)
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Why Amgen Still Has Valuation Upside RemainingValuentum • Fri, Feb 15 -
-
Is Amgen Running Out Of Steam In 2013?StockRiters • Tue, Jan 22 -
-
-
-
-
-
-
Amgen Management Discusses Q3 2012 Results - Earnings Call TranscriptTue, Oct 23, 2012
-
Amgen Management Discusses Q2 2012 Results - Earnings Call TranscriptThu, Jul 26, 2012
-
Amgen's CEO Discusses Q1 2012 Results - Earnings Call TranscriptTue, Apr 24, 2012
-
Amgen's CEO Discusses Q4 2011 Results - Earnings Call TranscriptThu, Jan 26, 2012
-
Amgen's CEO Discusses Q3 2011 Results - Earnings Call TranscriptMon, Oct 24, 2011
-
Amgen's CEO Discusses Q2 2011 Results - Earnings Call TranscriptFri, Jul 29, 2011
-
Amgen's CEO Discusses Q1 2011 Results - Earnings Call TranscriptWed, Apr 20, 2011
-
Amgen's CEO Discusses Q4 2010 Results - Earnings Call TranscriptTue, Jan 25, 2011
-
Amgen Management Discusses Q3 2010 Results - Earnings Call TranscriptTue, Oct 26, 2010
-
Amgen Q2 2010 Earnings Call TranscriptFri, Jul 30, 2010
-
Amgen Inc. Q1 2010 Earnings Call TranscriptThu, Apr 22, 2010
-
Amgen, Inc. Q4 2009 Earnings Call TranscriptMon, Jan 25, 2010
-
Amgen, Inc. Q3 2009 Earnings Call TranscriptWed, Oct 21, 2009
-
Amgen, Inc. Q2 2009 Earnings Call TranscriptTue, Jul 28, 2009
-
Amgen Inc., F1Q09Earnings Call TranscriptThu, Apr 23, 2009
-
PR Newswire (Wed, 5:46PM)
-
at CNBC.com (Mon, 6:43PM)
-
PR Newswire (Thu, 4:18PM)
-
PR Newswire (May 15, 2013)
-
PR Newswire (May 9, 2013)
-
at CNBC.com (May 1, 2013)
-
at CNBC.com (Apr 26, 2013)
-
at MarketWatch.com (Apr 26, 2013)
-
at CNBC.com (Apr 24, 2013)
-
at CNBC.com (Apr 24, 2013)
-
at MarketWatch.com (Apr 24, 2013)
-
at CNBC.com (Apr 24, 2013)
-
at CNBC.com (Apr 24, 2013)
-
at CNBC.com (Apr 23, 2013)
-
at CNBC.com (Apr 23, 2013)
-
at CNBC.com (Apr 23, 2013)
AMGN vs. ETF Alternatives
Company Description
Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” and “us”) is the world’s largest independent biotechnology medicines company. We discover, develop, manufacture and market medicines for grievous illnesses. We focus solely on human therapeutics and... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Sunday, October 18, 2009, 2:55 AM Pfizer's (PFE) experimental oral rheumatoid arthritis drug was effective both as a standalone and in combination with standard treatments, a final analysis of data from mid-stage studies shows. "People should be extremely excited about it," lead researcher Dr. Roy Fleischmann says, noting it should be cheaper than current biotech solutions like Abbott's (ABT) Humira and Amgen's (AMGN) Enbrel. Comment!
- Monday, September 21, 2009, 9:17 AM Amgen's (AMGN +2% premarket) Phase III trial of its under-the-skin osteoporosis drug denosumab delayed skeletal-related events (fractures etc.) for 20.6 months vs. 16.3 months for intravenously-injected rival Zometa (NVS -1%). (PR) Comment!
- Friday, September 18, 2009, 10:55 AM Roche (RHBBY.PK) is conceding defeat in its patent battle with Amgen (AMGN) over anemia drugs Epogen and Aranesp, court filings show. Comment!
- Sunday, September 6, 2009, 7:01 AM Amgen (AMGN) is working on a promising bone-loss treatment called denosumab. If, as expected, the treatment gets FDA approval, Barron's Dimitra Defotis explains how the stock could climb from a recent $58.95 to $78. 1 Comment
- Friday, August 14, 2009, 12:53 PM Analysts say Thursday's FDA panel on Amgen's (AMGN) experimental bone drug denosumab was surprisingly cautious, pointing to a more modest adoption than expected. The panel voted in favor of using the drug to treat post-menopausal women with osteoporosis, and men with prostate cancer, but against using it for breast cancer patients and for post-menopausal women at risk of osteoporosis. Comment!
- Tuesday, August 11, 2009, 11:54 AM Amgen (AMGN +0.6%) pops after the FDA publishes briefing notes for Thursday's advisory committee meeting about Amgen's experimental bone strengthening medicine, denosumab. 1 Comment
- Tuesday, July 28, 2009, 7:41 AM Amgen (AMGN) and GlaxoSmithKline (GSK) agree to jointly market an osteoperosis treatment that could see annual sales of $2B within a decade if approved by regulators. Premarket: AMGN +3.3%. 1 Comment
- Monday, July 27, 2009, 4:07 PM Amgen (AMGN): Q2 EPS of $1.29 beats by $0.13. Revenue of $3.7B (-1%) vs. $3.6B. Raises full-year EPS guidance to $4.80-4.95 vs. $4.57. Shares +2.5% AH. (PR) 2 Comments
- Monday, July 27, 2009, 12:10 AM Notable earnings after Monday's close: ACE, AMGN, CF, FNF, HMA, HXL, KRC, MAS, MTW, OLN, PCL, SLG, TMK, WRB Comment!
- Wednesday, July 8, 2009, 9:05 AM Amgen (AMGN) +16% premarket after announcing its experimental bone strengthening medicine, denosumab, demonstrated superior efficacy compared to potential rival Zometa (NVS) in a pivotal Phase-3 head-to-head trial. The results may allow Amgen to charge 20% more than anticipated. Comment!
-
Wednesday, July 8, 2009, 9:00 AM
Premarket gainers: AMGN +16%. MSCS +12%. FDO +8%. RFMD +7%. LVS +6%. DRYS +5%. AMLN +4%.
Losers: XNPT -13%. AIB -5%. AIG -4%. CTIC -4%. Comment! - Tuesday, June 16, 2009, 9:49 AM Sanofi-Aventis (SNY +1.6%) may be on the prowl for a mega pharma deal. Obvious targets include Bristol-Myers (BMY) and Amgen (AMGN), but smaller fry like Allergan (AGN) and Biogen Idec (BIIB) would be easier for SNY to digest without impairing its investment-grade credit rating. Comment!
- Thursday, April 23, 2009, 4:13 PM Amgen (AMGN): Q1 EPS of $1.08 misses by $0.07. Revenue of $3.31B (-8.4%) vs. $3.63B. Full-year guidance in line with expectations. Shares -3.7% AH. (PR) Comment!
- Thursday, April 23, 2009, 3:10 PM Notable earnings after Thursday's close: ACF, AMGN, AMZN, ATHR, AXP, BNI, BUCY, CAKE, CB, CF, CNW, CRBC, CYH, CYN, DDR, DDUP, DV, EMN, FII, INFA, JNPR, KLAC, MHK, MSCC, MSFT, NFLX, PKI, PMCS, RIO, RMBS, RVBD, SPWRA, STAR, STSA, SWKS, SYNA, WDC, WFR, YRCW Comment!
- Thursday, April 23, 2009, 12:10 AM Notable earnings after Thursday's close: ACF, AMGN, AMZN, ATHR, AXP, BNI, BUCY, CAKE, CB, CF, CNW, CRBC, CYH, CYN, DDR, DDUP, DV, EMN, FII, INFA, JNPR, KLAC, MHK, MSCC, MSFT, NFLX, PKI, PMCS, RIO, RMBS, RVBD, SPWRA, STAR, STSA, SWKS, SYNA, WDC, WFR, YRCW Comment!
- Tuesday, April 7, 2009, 3:26 PM On Friday, in a little-noticed ruling likely to make biotech patents harder to obtain in the future, a federal appeals court answered with a definitive yes. Amgen (AMGN) takes the hit, but the implications for research could be significant. Comment!
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
O. Young Kwon
Amgen (AMGN), Nike (NKE), Cemex (CX), and First Solar (FSLR) have their TANER momentum. See "Income Portfolio Adjustments by the TMT..." yk - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
LATEST REPLIES